News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Sermo Healthcare Community Expands Payer & Oncologist Reach To Support Evolving Industry Needs

Sermo

Sermo, a physician-first online community and leader in global healthcare professional (HCP) insights, has expanded its platform to offer industry customers on-demand access to critical payer insights and the opportunity to build stronger connections with oncologists at a time when cancer treatment innovations are on the rise globally. The recent acquisitions of Payer Access, a leading insights provider in the U.S. payer and hospital decision-maker market followed by Charter Oak, a premier healthcare research company, support and amplify payers and oncologists on Sermo. Now, Sermo provides comprehensive reach across HCPs, payers and expert healthcare decision-makers within a single platform. Sermo’s reach into the U.S. payer market exceeds 230 million commercial lives covered. With the inclusion of Pharmacy Benefit Management companies, their reach covers virtually every commercial life in the United States. Pharmaceutical and medical device companies can leverage this highly coveted group to inform successful go-to-market strategies ranging from new product receptivity to defining win-win contracting terms. In addition to the payers expansion, Sermo is dedicated to building the Sermo Oncology Community further through its multi-channel recruitment and engagement strategy. Given the highly competitive oncology market and an ASCO-projected shortage of more than 2,200 oncologists by 2025, trusted oncologists’ insights and engagements are in high demand by the entire healthcare ecosystem. Since 2018, Sermo’s global Oncology community has grown by 28% and is projected to reach 42,000+ by the end of 2023. The growth enables Sermo to connect with more oncologists, make their voices heard on the platform and share vital insights to inform healthcare decisions around the world. “This strategic expansion is a testament to Sermo’s ongoing growth trajectory and directly fills gaps in the healthcare industry’s needs,” said Sermo CEO, Peter Kirk. “With Sermo’s global reach of 1.3 million HCPs, acquisitions such as Charter Oak and Payer Access give us increased 360-degree market visibility, added connections to the oncology community and unique access to essential audiences that directly impact outcomes for millions.” As the healthcare industry continues to evolve and tackle important trends like an increase in cancer rates among patients globally, Sermo is committed to providing a trusted platform for real-time insights and engagements among crucial stakeholder groups. These acquisitions are important milestones in Sermo’s continued M&A and growth strategy. About Sermo: Sermo turns physician experience, expertise and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries as well as the U.S. payer community, Sermo provides a unique community that fosters impactful peer-to-peer collaboration and discussions about issues that are important to healthcare constituents and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners and the medical community at large. To learn more, visit www.sermo.com. Contact Details Sermo Kite Hill PR for Sermo sermo@kitehillpr.com Company Website https://www.sermo.com/

February 08, 2023 10:00 AM Eastern Standard Time

Article thumbnail News Release

MGC Pharmaceuticals' "numbers were very good" in Q4 2022

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive's Thomas Warner about how the business performed during the fourth quarter of 2022. Clements says that the "numbers were very good" and reveals more details about how the business is changing as it heads into a new calendar year. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2023 08:47 AM Eastern Standard Time

Video
Article thumbnail News Release

Skye Bioscience marks SBI-100 clinical trial progress with new clinical research organization

Skye Bioscience Inc

Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials. SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness. Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. Contact Details Proactive Investors US +1 347-449-0879 na-editorial@proactiveinvestors.com

February 08, 2023 07:19 AM Eastern Standard Time

Video
Article thumbnail News Release

UC Asset Signed 2nd MoU to Speed Up Phase I of $4M Cannabis Deal

UC Asset LP

McapMediawire -- UC Asset LP (OTCQB: UCASU ) announced today that the company has signed second MOU on its recently announced deal of $4 million cannabis property transaction in the State of Oklahoma. Four weeks ago, UCASU entered into a MOU to acquire a 10,000 square foot cannabis cultivation property using $3 million non-cash payment, and to invest $1 million cash to build extra 5,000 square feet of facility at the same site. The new MOU details on what UCASU calls “Phase I” of the deal. In this Phase I, UC Asset will acquire 20% of ownership in the said property using non-cash payment of 500,000 preferred shares, and then will invest $1 million cash for the aforementioned expansion of the cultivation facility, while increasing UC Asset’s ownership to 50%. UC Asset will have the option to acquire the remained 50% ownership of the property by issuing 2 million preferred shares. “The updated plan of Phase I enables us to expediate the construction of the extra 5,000 square feet of cannabis cultivation facility, and therefore it will speed up the return from our investment,” claims Larry Wu, founder of UC Asset. “Now we are expecting to receive monthly payment after 3 months, in comparison to the previous plan under which we will only be paid after 6 months.” This expedition is a win-win solution for both parties, according to Wu. The State of Oklahoma will hold a special election in March to decide on marijuana legalization. It is projected that the result will be in favor of legalization. For this reason, it is very desirable to complete the said expansion of growing facility as soon as possible, possibly right after the legalization of recreational marijuana within the state. Most other terms and conditions remain the same, including the amount of monthly payment that UC Asset will receive, which will represent a 14.4% cash on cash annual return. It will still include protective terms for existing shareholders, so that the issuance of 500,000 preferred shares will not dilute the value of holdings by existing shareholders, particularly, it will not dilute dividends allocated to existing shareholders. This is possible since the preferred shares are not entitled to receive dividends unless converted into common shares, and the holder of preferred shares can only convert when revenue from the property has increased to a certain level. This 10,000 square foot cannabis property, according to UC Asset, is built to the state-of-art standard, with computerized and automatized environment control, and has the capacity to host full cycle cannabis production from creating clones/genetics to extracting cannabinoids. UC Asset has set a goal of $1 million gross profit for the year of 2023. And the speed-up of this deal will likely help UC Asset to reach that goal. About UC Asset LP UC Asset LP is a limited partnership formed for the purpose of investing in real estate with innovative strategies. For more information about UC Asset, please visit: www.ucasset.com Disclaimer: This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed. For More Information Contact: IR@UCasset.com Contact Details Larry Wu IR@UCasset.com Company Website http://www.ucasset.com/

February 07, 2023 12:43 PM Eastern Standard Time

Article thumbnail News Release

Context Therapeutics announces positive responses in Phase 2 OATH clinical trial

Context Therapeutics

Context Therapeutics CEO Marty Lehr joined Proactive's Natalie Stoberman to announce two clinical responses from its Phase 2 OATH Clinical Trial. Lehr said two patients have achieved a confirmed partial response among the first 12 patients enrolled in the trial evaluating the potential of ONA-XR in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer. The findings are encouraging as ONA-XR exhibits initial signals of clinical activity and confirmed tumor shrinkage, Lehr added. Contact Details Proactive Investors USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 07, 2023 12:21 PM Eastern Standard Time

Video
Article thumbnail News Release

Avicanna completes first international export of cannabis seeds between Colombia and Spain

Avicanna Inc

Avicanna CEO Aras Azadian joined Proactive's Natalie Stoberman to discuss the completion of its first export of feminized cannabis seeds to Spain. Azadian said the company's majority-owned Colombian subsidiary, Santa Marta Golden Hemp SAS, sent its first commercial export of feminized cannabis seeds to Spain. The seeds are part of the Aureus portfolio of products which also includes proprietary genetics in the form of feminized seeds, cannabinoid extracts and purified compounds including CBD, CBG and THC. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 07, 2023 12:14 PM Eastern Standard Time

Video
Article thumbnail News Release

Braxia Scientific signs non-binding letter of intent to sell company to Irwin Naturals

Braxia Scientific Corp.

Braxia Scientific CEO Dr Roger McIntyre joined Steve Darling from Proactive to share news the company has agreed to a non-binding amended and restated letter of intent for a business combination with Irwin Naturals Inc. McIntyre told Proactive the transaction assembles an experienced management and scientific team in mental health treatment, research and development. The combined company will have 17 specialized mental health clinics across North America, an enhanced telehealth platform and access to critical treatments for millions of people across multiple states in the US. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

February 07, 2023 12:02 PM Eastern Standard Time

Video
Article thumbnail News Release

Freedom Holdings Closes with MEDcann Industries, Inc.

FREEDOM HLDG INC.

MCapMediaWire -- Freedom Holdings, Inc. aka Freedom Acquisition Corp (OTC: FHLD ) (“FHLD” or the "Company”), is pleased to announce that it has closed on the Definitive Agreement with MEDcann Industries as announced. The Closing took place on February 3, 2023, and the terms of the agreement have been consummated as follows: MedCann has purchased 40,000,000 Freedom restricted common shares for $50,000.00 and Brian Kistler has resigned all Officer/Director positions only to serve as an advisor for a period of 2 years to insure a smooth transition and John Vivian, CEO of MedCann has been appointed as the Chairman and CEO of Freedom, Robin Wright as C.F.O. and MEDcann (as the parent company) has assumed the debt and ongoing operational costs of Freedom. All financial disclosures are to be brought current. Brian Kistler, outgoing CEO, and Director stated: “This opportunity for the Company to take on the operations of MedCann Industries as a majority owned subsidiary will launch Freedom into the lucrative Cannabis industry for future development. I am pleased for the control of the Company to be taken over by the new management for a breath of new life for all of the shareholders.” John Vivian, incoming CEO and Chairman of the Board commented “I want to thank Brian for his confidence in our ability to take Freedom to new levels of shareholder value as we execute our plan of moving all operations into Freedom just as soon it is possible. We will update our shareholders as the plan unfolds.” “I am also pleased to have Ms. Wright join me on the Board of Directors and believe that our future is bright with their influence and expertise” concluded Vivian. BUSINESS DESCRIPTION: MEDcann Industries, Inc. - Medical Cannabis, Inc. is a developer and provider of next generation Cannabis driven products such as CBD & THC, cannabis 420 beverages, and Medical treatment solutions with Cultivation to help customers and patients increase their medical health and treatments to improve their illnesses and Cancers. Press Release Contact: John Vivian CEO MEDcann Industries, Inc 813-699-4098 Safe Harbor Statement This press release contains statements, which may constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief, or current expectations of the Company, members of its management, and assumptions on which such statements are based. We caution prospective investors that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Contact Details MEDcann Industries, Inc John Vivian +1 813-699-4098

February 07, 2023 09:00 AM Eastern Standard Time

Article thumbnail News Release

InnerScope Hearing Technologies (OTC: INND) Featured in Official 2023 Super Bowl LVII Game Program

Innerscope Hearing Technologies, Inc.

2023 Official NFL Super Bowl LVII Game Program 1 Million Hard Copies 50 Million Unique Visitors - Digital Edition 500 Million Page Views - Digital Edition McapMediaWire -- InnerScope Hearing Technologies Inc. (OTC: INND ) ("InnerScope"), an emerging and disruptive leader in the Over-the-Counter (OTC) Hearing Aid space today announced its print ad campaign "Hearing Made Easy" is featured in the Official Super Bowl LVII (57) Game Program. Super Bowl LVII is a showdown between the AFC Champions, Philadelphia Eagles, and the NFC Champions, Kansas City Chiefs. The kickoff is this Sunday, February 12th, at 6:30 pm EST, with Chris Stapleton singing the National Anthem and international icon Rihanna taking center stage for Apple Music Super Bowl Halftime Show. The Official NFL Super Bowl LVII Commemorative Souvenir Game Program features InnerScope's print ad campaign strategically placed on page 229 opposite a full editorial that recaps the first four weeks of the Philadelphia Eagles regular season. The print ad campaign highlights a message of "Hearing Made Easy" – No Prescription Needed – No Medical Exam Needed with InnerScope's iHEAR and HearingAssist brand of Medical-Grade FDA-registered OTC rechargeable hearing aids starting at $499 a pair. The ad also includes a list of selected in-store and online major retailers where iHEAR and/or HearingAssist OTC hearing aids can be purchased, including Walmart Vision Centers, Walmart.com CVS.com, Bestbuy.com, RiteAid, RiteAid.com or directly from iHEARdirect.com or HearingAssist.com. NFL Super Bowl LVII Game Program will be made available to the fans during the game with exclusive distribution rights inside State Farm Stadium on Sunday, February 12, 2023. In addition, the publication will be made available for purchase nationwide at major newsstands, bookstores, hotels, mass and specialty stores, supermarkets, pharmacies, international airports, and online at NFLShop.com at a cover cost of $20 with a circulation of nearly 1,000,000 hard copies with 100% sell-thru and a pass along the value of approximately 5,000,000 (5 readers per copy). In addition to in-stadium and retail distribution, a robust digital component is included to enhance the visibility significantly: In the week preceding and following the game, the digital edition of the 2023 Official NFL Super Bowl LVII Game Program will be made available for free viewing on NFL.com. NFL.com expects to receive more than and experience approximately during this time. To view the digital edition of the 2023 Official NFL Super Bowl LVII Game Program, click the link here: Official Super Bowl 57 Game Program (hozinc.com). To View InnerScope's "Hearing Made Easy" print ad, type in the search box page 229. Also, in addition to the activation on NFL.com, All-Star Players and Media Personalities, with nearly 14 million combined opt-in followers, have agreed to share the publication over social media with their respective followers. FDA Ruling On OTC Hearing Aids Is A Game Changer For InnerScope An "FDA Ruling on OTC Hearing Aids went into effect on October 17, 2022, allowing millions of Americans with hearing loss to purchase hearing aids without a prescription, medical exam, or needing a professional to fit the hearing aids. But until the FDA ruling, getting hearing aids required a medical exam, prescription, and fitting done by an audiologist. In addition, the cost of professionally fitted hearing aids averages over $5,000 out-of-pocket costs for a pair because Medicare or private insurance plans don't typically cover the devices. However, FDA has established that OTC hearing aids are safe and effective for adults with perceived mild to moderate hearing loss and are regulated as medical devices by FDA. In addition, according to the National Institute on Deafness and Other Communication Disorders, as many as 30 million adults in the United States currently have some degree of hearing loss and would benefit from using hearing aids. The FDA ruling was a game changer for InnerScope since its iHEAR, and HearingAssist brands of OTC hearing aids have the same type of technology and features as hearing aids sold and fit by hearing healthcare professionals at an average saving of $3,000 to $4,000 per pair. Additionally, InnerScope's iHEAR and HearingAssist OTC hearing aids are designed for consumers with perceived mild to moderate hearing loss with many different models that feature Bluetooth App-Controlled and Full-Streaming for Hands-Free Phone Calling and Listening to Music and/or Podcasts. "We are proud to have our "Hearing Made Easy" ad campaign featured in the Official NFL Super Bowl LVII Commemorative Souvenir Game Program, said Matthew Moore, President and CEO of InnerScope Hearing Technologies. "Forbes has listed the Super Bowl as "the world's most valuable sporting event brand. The Official Super Bowl LVII Game Program is simply the most valuable, content-rich magazine in all sports. In addition, we believe InnerScope's iHEAR and HearingAssist OTC Hearing Aid brands associated with the Super Bowl brand and our "Hearing Made Easy" campaign print ad will provide awareness to millions of people that need hearing aids but, up until now, could never afford them." About InnerScope Hearing Technologies, Inc. (OTC: INND): InnerScope Hearing Technologies Inc. is a manufacturer and distributor of OTC Hearing Aids, Hearing Aid Accessories & Hearing Health-Related Products ("Hearing Products") dedicated to addressing the global demand for affordable hearing solutions. InnerScope's Hearing Products and its B2C and B2B business model break through the barriers that prevent access to effective and affordable hearing solutions. InnerScope's recent acquisition of iHear Medical Inc., a Direct-to-Consumer ("DTC") cloud-based hearing solution provider, gives the Company access to over 40 patents and an R&D facility. In addition, InnerScope has acquired HearingAssist, an established leader since 2008 in the DTC hearing aid market, with a customer base of over 400,000. These acquisitions, combined with a partnership with Atlazo Inc., a semiconductor innovator for next-generation AI smart devices, will allow InnerScope to better position itself in the OTC hearing aid market by selling advanced Hearing Products through Walmart and many other major retailers and pharmacy chains. InnerScope's full line of Hearing Products is currently available through these multiple retail/wholesale distribution channels: Walmart Vision Centers, Walmart.com, Walmart Canada, CVS.com, RiteAid.com, BestBuy.com, Amazon.com, Fingerhut.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, Cardinal Health™ at-Home, Carewell.com FSAStore.com, HSAStore.com, WellDeservedHealth.com, Wakefern Food Corp. / ShopRite, SpartanNash / VG's Grocery / Family Fare / Martin's Super Markets and Topco Associates representing 1000's of stores. Coming Soon: More major retailers and pharmacy chains for InnerScope's in-store and online Hearing Products. For information related to InnerScope Hearing Technologies' latest hearing aids and related hearing products, please visit: http://iheardirect.com http://hearingassist.com For the most up-to-date information about InnerScope Hearing Technologies (OTC: INND), please visit and follow our official Twitter account @inndstock page: https://twitter.com/inndstock InnerScope Hyperlinks: HearingAssist HearingAssist - Walmart.com HearingAssist - CVS.com HearingAssist - RiteAid.com HearingAssist - BestBuy.com iHEAR iHEAR - CVS.com Acquisition of iHear Medical Inc. Acquisition of HearingAssist Safe Harbor This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, intended to be covered by the "safe harbor" created by those sections. Any statements that are not historical facts contained in this press release are also "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA). Such statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be canceled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing or maintain contractual relationships with vendors and customers, competition, general economic conditions and other factors that are detailed in our periodic reports filed with the Securities and Exchange Commission ("SEC"). We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA, Securities Act, and Securities Exchange Act. Contact: InnerScope Hearing Technologies, Inc. Investor Relations ir@innd.com 833-788-0506 www.innd.com Investor Relations Agency Contact: Skyline Corporate Communications Group, LLC Lisa Gray, Senior Account Manager One Rockefeller Plaza, 11th Floor New York, NY 10020 Office: (646) 893-5835 Email: lisa@skylineccg.com Contact Details InnerScope Hearing Technologies, Inc. Investor Relations +1 833-788-0506 ir@innd.com Skyline Corporate Communications Group, LLC Lisa Gray, Senior Account Manager +1 646-893-5835 lisa@skylineccg.com Company Website http://www.innd.com/

February 07, 2023 08:30 AM Eastern Standard Time

1 ... 144145146147148 ... 256